Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting

Affiliations

• ¹ Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
• ² Department of Pharmacology, University of Extremadura, Cáceres, Spain.
• ³ Division of Drug Research, Department of Medical and Health Sciences, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
• ⁴ Mayo Clinic, Rochester, Minnesota, USA.
• ⁵ Moffitt Cancer Center, Tampa, Florida, USA.
• ⁶ Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
• ⁷ Affymetrix, Santa Clara, California, USA.
• ⁸ HUGO Gene Nomenclature Committee (HGNC), EMBL-EBI, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, UK.
• ⁹ St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
• ¹⁰ Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
• ¹¹ Millennium Health, LLC, San Diego, California, USA.
• ¹² Department of Human Genetics and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
• ¹³ US Food and Drug Administration, Silver Spring, Maryland, USA.
• ¹⁴ Agena Bioscience, San Diego, California, USA.
• ¹⁵ Indiana University School of Medicine, Indianapolis, Indiana, USA.
• ¹⁶ Division of Clinical Pharmacology and Therapeutic Innovation, Children's Mercy Kansas City and School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
• ¹⁷ Translational Software, Bellevue, Washington, USA.
• ¹⁸ Department of Genetic Analysis, Thermo Fisher Scientific, South San Francisco, California, USA.
• ¹⁹ Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
• ²⁰ Department of Genetics, Stanford University, Stanford, California, USA.
• ²¹ National Institutes of Health / National Library of Medicine / National Center for Biotechnology Information, Bethesda, Maryland, USA.
• ²² University of Utah and ARUP Laboratories, Salt Lake City, Utah, USA.
• ²³ University of Basel, Basel, Switzerland.
• ²⁴ Department of Psychiatry, University of Toronto, CAMH, Toronto, Ontario, Canada.
• ²⁵ Department of Genome Sciences, University of Washington, Seattle, Washington, USA.
• ²⁶ Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.
• ²⁷ Aegis Science Corporation, Nashville, Tennessee, USA.
• ²⁸ Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, University Hospital, Tuebingen, Germany.
• ²⁹ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
• ³⁰ Genelex Corporation, Seattle, Washington, USA.
• ³¹ Coriell Institute for Medical Research, Camden, New Jersey, USA.
• ³² CAMH and the Departments of Psychiatry and Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
• ³³ Department of Clinical Chemistry, Erasmus MC Rotterdam, International Federation for Clinical Chemistry (IFCC) Task Force Pharmacogenetics, Rotterdam, The Netherlands.
• ³⁴ Department of Pathology, The University of Chicago, Chicago, Illinois, USA.